Table 1.
Patients and baseline characteristics of the 730 secondary metastatic patients, at the moment of early breast cancer
| Sex, n/N (%) | |
| Male | 7/730 (1) |
| Female | 723/730 (99) |
| Mean age at diagnosis of primary breast cancer, yearsa | 56 ± 13 |
| Menopausal status, n/N (%) | |
| Premenopausal | 262/730 (36) |
| Postmenopausal | 436/730 (60) |
| Perimenopausal | 25/730 (3) |
| Not applicable (male) | 7/730 (1) |
| Mean CA 15.3 value at moment of diagnosis of early breast cancer, kU/la | 25 ± 73 |
| Tumour characteristics of primary surgery group, n/N (%) | 548/730 (75) |
| Pathological tumour size n/N (%) | |
| pT1 | 161/548 (29) |
| pT2 | 296/548 (54) |
| pT3 | 88/548 (16) |
| pT4 | 3/548 (1) |
| Pathological nodal status, n/N (%) | |
| pN− | 200/548 (36) |
| pN+ | 348/548 (64) |
| Tumour characteristics of neoadjuvant group, n/N (%) | 182/730 (25) |
| Clinical tumour size, n/N (%) | |
| cT0 | 1/182 (1) |
| cT1 | 9/182 (5) |
| cT2 | 34/182 (19) |
| cT3 | 41/182 (22) |
| cT4 | 97/182 (53) |
| Clinical nodal status, n/N (%) | |
| cN− | 28/182 (15) |
| cN+ | 154/182 (85) |
| Clinical subtype of the primary breast tumour, n/N (%) | |
| Luminal A-like | 264/730 (36) |
| Luminal HER2-like | 52/730 (7) |
| Luminal B-like | 215/730 (30) |
| HER2-like | 56/730 (8) |
| Triple-negative | 143/730 (19) |
| Treatment setting, n/N (%) | |
| Neoadjuvant treatment | 182/730 (25) |
| Luminal A-like | 58/182 (32) |
| Luminal HER2-like | 16/182 (9) |
| Luminal B-like | 32/182 (17) |
| HER2-like | 23/182 (13) |
| Triple-negative | 53/182 (29) |
| Upfront surgery | 548/730 (75) |
| Luminal A-like | 206/548 (38) |
| Luminal HER2-like | 36/548 (7) |
| Luminal B-like | 183/548 (33) |
| HER2-like | 33/548 (6) |
| Triple-negative | 90/548 (16) |
HER2, human epidermal growth factor receptor 2.
a
Mean ± standard deviation.